Welcome To M-Tubulin

  • Phone : 615.386.7000
  • 40 Burton Hills Blvd, Suite 200, Nashville, TN 37215

Our Lead Molecule
MLS-222QLD

MLS-222QLD is relevant for the treatment of many cancers.  It can serve as either a standalone or synergistically as a combination therapy.

 Therapeutic Strategy

Standalone or Combination Treatment Option

M-Tubulin molecules are novel, first-in-class, botanically inspired for the treatment of many cancers.  Our molecules have promising single agent activity that can act synergistically in combination with targetted therapies.  Our molecules are vetted through our parent company’s proprietary Artificial Intelligence (AI) based virtual representation of the human body. The end result, a therapeutic that’s both highly effective with much lower toxicity and side effects compared to existing drugs on market.

 Initial Indication: Glioblastoma Multiforme, GBM

38% vs 16% results
Glioblastoma is one of the most deadly cancers with limited treatment options.  Glioblastoma is the most common primary brain cancer in adults, accounting for approximately 75% of malignant brain tumors.  More than 14,490 Americans are expected to receive a GBM diagnosis in 2023. Even with aggressive treatment options including surgery, radiation, and chemotherapy, long term survival rates remain poor.
M-Tubulin is advancing MLS-222QLD, as it has been shown to significantly prolong survival in animal models. The targets are tubulin (colchicine binding domain) and NF-kB; two pathways associated with GBM growth and proliferation.

Molecule Screening

Tested via National Cancer Institute.  Tested in Animals and Exhaustively Screened via M-Life’s AI Based P2L/MiST™ Platforms for Efficacy and Toxicity
The M-Tubulin portfolio includes eight Tubulin/NFκB acting molecules, with MLS-222QLD and MLS-220QLD demonstrating the highest performance.  MLS-222QLD is the current lead molecule.  Testing results show the promise as a superior treatment option across a wide range of cancers, including GBM and AML.  The National Cancer Institute’s NCI-60 panel along with M-Life’s Artificial Intelligence (AI) based assessments substantiate efficacy across a multitude of cancer cell lines.  All preclinical Contract Research Organization (CRO) animal/culture testing results align with M-Life AI screening.  Toxicity assessment included, QT/Torsades/hERG (Cardiotoxicity); Agranulocytosis (Neutropenia); Mitochondrial, Primary and Secondary Amine Mutagenicity; Hepatotoxicity; and Ocular Toxicity. Benchmark comparative assessments of MLS-222QLD indicate lower toxicity, higher potency along with excellent drug-like properties consistent with a first-in-class drug.
Treated & Untreated Mice

AML Cancer grafted mice after 7 days.  Untreated mouse, left, displays significant cancer proliferation (blue fluorescence=high density of cancer cells; red=low density of cancer cells).  MLS-222QLD treated mouse right displays little AML proliferation except in a small area adjacent to the heart at low density.

 Background Story

Eric Rubenstein, MD—Cancer impacts everyone and increasingly so as we get older. It is the 2nd leading cause of death in the US and a leading cause of mortality and morbidity worldwide. Whatever your station in life, we all have seen the effects of cancer on family and friends. GBM is one of those uniquely tragic malignancies, as it strips patients of their dignity and autonomy; without the realistic consolation of effective treatment options for most.
The CEO of our parent Company, Ted Moskal, lost his father to GBM in 2003. His father was a very healthy, active man, diagnosed with a GBM a few months after retirement. Neurosurgeons removed a tennis-ball-sized tumor from his right hemisphere paralyzing his left side. He received chemo-radiation therapy…and the region of tumor resection was clear of cancer for about 5 months. Unfortunately, within weeks the tumor recurred in its entirety and he succumbed to the diseased a mere 3 ½ months later. From a physicians perspective this is a typical case of GBM, in the usual demographic, and even for a vigorous and healthy patient.
Some 20 years later, I have witnessed this same story playout with too many patients. In fact chemo-radiation with temozolomide offers a meager 2.5 months improvement in overall survival. In late 2017 the FDA approved single agent bevacizumab despite a lack of survival benefit, life expectancy remains exceedingly short; typically less than 15 months. Even in 2023 for a typical IDH wildtype GBM without MGMT hypermethylation promoter, advanced molecular profiling and classification determine prognosis more often than guides therapeutic intervention. The solution, I believe, will come by looking at the problem in new ways. It will come through availing new therapeutic tools and combining them in unique ways to make them specific to each malignancy. This is our approach at M-Tubulin, as well as at our parent M-Life.
Our hope for MLS-222QLD is that it will not only arrest and reverse GBM tumor growth, but its favorable toxicity profile will provide patients with a more meaningful benefit. The novel M-Tubulin molecule binds to the colchicine-tubulin moiety; our Development Team discovered and augmented a second mechanism—in this case the NF-kB pathway inhibition. The design and engineering effort required was extraordinarily complex targeting two different targets, minimizing adverse effects, and optimizing bio-availability while traversing the blood-brain barrier. Despite the complexity, the animal testing and modeling results for MLS-222QLD are extremely encouraging. Furthermore National Cancer Institute cell line testing and M-LIfe’s Artificial Intelligence based results have convinced us that MLS-222QLD may serve as a foundational therapeutic for many other cancers. Alas, Artificial Intelligence is finally being utilized in ways we the practicing oncologists have always dreamed; but now can envision!